Curia’s Approach to Rapid Scale up and Development
The webinar will focus on truncating drug development timelines in the aftermath of Covid. The featured speaker will lay emphasis on phase-appropriate development, offering creative solutions and round the clock development across various continents.
The webinar will also highlight tech transfer into various sites within the Curia network. Using a global sourcing team to find raw materials that have a diversified supply chain, the speaker will discuss how they have adapted and learnt lessons from the Covid outbreak.
Join this webinar to learn how to accelerate drug development timelines in the post-Covid era.
Ravi Rai, Director, Chemical Development, Curia Global, Inc.
Ravi Rai received his PhD in carbohydrate chemistry from Utah State University in 2006. He then pursued an industrial post doctorate at a CRO called Organix Inc. in Woburn, MA. Ravi joined Curia in 2007 as a Senior Research Scientist in the medicinal chemistry department where he worked on a diverse range of customer projects primarily developing an SAR based library of compounds that had the desired efficacy for the targets that were being pursued.
He currently heads the process development group in Albany and has oversight of all the development programs that are being worked on and oversees their transition through various phases of development and scale up in Curia’s kilo lab and GMP suites. He also oversees tech transfer to other global sites within the Curia network. On the business front, he serves as an SME on pre-RFP projects with potential customers advocating for phase-appropriate development, educating potential customers on potential pitfalls during rapid scale-up and presenting the big picture to ensure that their programs are successfully executed with a QbD mindset.
Who Should Attend?
- Small & large Biotechs
- Big pharma
- Virtual companies
What You Will Learn
Attendees will gain insights into:
- Phase-appropriate drug development
- Linear vs. convergent synthesis
- Quality by Design (QbD) in route of synthesis
- Effective technology transfer
Curia is a Contract Research, Development and Manufacturing Organization with over 30 years of experience, an integrated network of 29 global sites and over 3,500 employees partnering with customers to make treatments broadly accessible to patients. Our biologics and small molecule offering spans discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to accelerate and sustain life-changing therapeutics. To learn more visit us at curiaglobal.com.